Home > Boards > US OTC > Food - Processing and Agriculture >


Add BEES Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/10/2021 12:30:58 PM - Followers: 24 - Board type: Free - Posts Today: 0


BEESFREE, Inc. Security Details

Contact Info
  • 2101 Vista Parkway Suite 403
  • West Palm Beach, FL 33411
  • Phone: 561-939-4860

Share Structure

Market Value  $49,291,671 a/o Feb 02, 2012
Shares Outstanding 15,166,668 a/o Oct 27, 2011
Authorized Shares 30,000,000 a/o Dec, 2011
Float N/A a/o Dec, 2011
Par Value 0.001



Transfer Agent

Island Stock Transfer

15500 Roosevelt Boulevard
Suite 301
Clearwater, FL, 33760




We are a technology company that develops and commercializes innovative solutions for the beekeeping community. We intend to operate on a global basis. We plan to manufacture and sell our patent-pending technology that dispenses and delivers our proprietary mixture of chemical compounds to the bee population in order to prevent the effects of colony collapse disorder, or CCD.


Colony Collapse Disorder.pdf


Plan of Operations



We currently intend to begin further research and development activities in the first quarter of 2012.  These research efforts will focus on the improvement and development of new features for our current BeesFree Dispenser.  On an ongoing basis, we also intend to ensure that our proprietary chemical compound mixture addresses the latest research with respect to bee healthcare and CCD.  We also intend to devote significant research and development resources to the development of a new version of the BeesFree Dispenser with more advance functionalities in the second half of 2012.


We have plans to create our own laboratory facility in Rome, Italy, where our chief scientist is located.  We anticipate that we will use this facility for research and development and chemical compound production, in addition to quality testing of our chemical compounds.  We foresee outsourcing the production of our chemical compound to third parties.


With respect to the hiring and retention of personnel, we anticipate that we will hire an additional four to seven regional sales managers in various regions throughout the world within the next twelve months, who will join our current regional sales manager in Argentina.  In addition, on the officer-level, we may hire a product manager to oversee production of our products.  Our estimated monthly costs with respect to the hiring of new personnel is between $25,000 and $40,000.


We own technology that was developed to remedy problems arising from CCD.  On August 27, 2011, we acquired the full rights to our patent-pending proprietary chemical compound and the BeesFree Dispenser from Dr. Francesca del Vecchio in exchange for 1,650,000 shares of BeesFree-DE. Our technology consists of a mix of chemical compounds, which contains natural and synthetic elements to combat honey bee parasites, mitigate the effects of neonicotinoid-based pesticides and provide nourishment to honey bees, and an innovative delivery system, the BeesFree Dispenser, which is scientifically-designed to attract bees with specific colors and shapes. We filed a patent with the Italian Patent Office (UIBM) and the Chamber of Commerce in Rome (in line with current Italian legislation) on August 26, 2011. In addition, we plan to proceed with an end-to-end filing process with WIPO (World Intellectual Property Organization) located in Geneva, Switzerland. WIPO is a world-wide organization which groups together all offices of the Patent Cooperation Treaty ("PCT") member countries. As discussed elsewhere in this Form 8-K, expect to target Argentina to market our product and we note that Argentina is not a member of the PCT, and therefore, we filed a PCT extension in Argentina which will protect our pending-patent in Argentina. We expect the final filing at WIPO, and the PCT extension in Argentina, to be finalized by end of January 2012. As such, our patent application is currently pending.

We currently have developed one integrated product, consisting of the BeesFree Dispenser (see rendering below) and our proprietary chemical compound.  The BeesFree Dispenser integrates a simple-to-use, fully-automated and innovative dispenser with a proprietary mixture of chemical compounds consisting of several specific agents, including:

antimicrobial agents and compounds to fight the invertebrate iridescent virus and its interaction with the Nosema fungus, considered by scientists to be contributing factors to CCD;
components to contrast the side effects of neonicotinoids, which are used in pesticides, on bees; and
other nutrients and antioxidants

The BeesFree Dispenser has been optimized to attract bees by means of specific colors and shapes and to feed them in their natural environment and habitat.  The components of the BeesFree Dispenser include:
a reservoir, where the proprietary mix of chemical compounds is mixed with water;
an atomizer, to spray the mixture of chemical compounds and water;
a distributor, with specific shapes and colors designed to attract bees; and
a multifunctional control system, to monitor, alarm and control the dispenser.
The BeesFree Dispenser operates using batteries and is rechargeable by a small solar panel.  The BeesFree Dispenser is designed to be placed amongst beehives in order to be easily accessible to bees. A bottle of approximately 34 ounces (1 liter) of our chemical compound is designed to last for approximately two to three months, assuming day-to-day distribution of the compound.  The BeesFree Dispenser is designed to last for up to a three year period of usage.

We intend to develop additional products to assist the bee population as our business matures.
Business Strategy
We participated in Apimundia 2011, the world largest fair and conference on beekeeping, held in Buenos Aires, Argentina where numerous sales contacts were established. We have also established relationships with national research and development institutes to run deployment projects in Argentina. Mr. Agostino Agamben, our Argentine sales manager, has been invited to present our BeesFree project at conferences and workshops
We have also initiated the registration and certification process in Italy and Argentina; upon approval we will be able to sell our chemical compound in other countries that are members of the EU and Mercosur, respectively. We intend to commence certification process (if needed) in the United States in the first half of 2012.
Our strategy is to minimize production costs for both the dispenser and the chemical compound outsourcing to different partners/vendors in various regions of the world rather than in one country, i.e. Italy. We believe that the continual efforts of internal research and development are necessary to maintain our technology leadership and to improve our solution to the worldwide problem of CCD.
We also intend to start an ecommerce program that will enable us to make direct sales to various regions of the world where ecommerce is widely used and accepted.



We have decided to begin our sales campaign in Argentina, because it is one of the top honey producing and exporting countries in the world and because of its favorable regulatory regime.   We intend to introduce our products into other countries and regions that are both major honey producers and that will require what we anticipate to be shorter waiting periods for regulatory approval than those waiting periods for comparable regulatory approval in the U.S.  We have determined our sales and marketing strategy based primarily upon these two factors: the volume of honey production and size of the bee population in a jurisdiction and the estimated complexity of the national regulatory environment where we may seek to enter the market.

Marketing, Sales and Distribution
We intend to retain overall control of our technology, product development and wholesale sales at a global level and we will engage international, national and regional existing wholesale distributors to market and distribute our products at a local level.  We believe that this wholesale distribution approach will significantly aid in limiting our fixed operating and sales costs.  In addition, we intend to develop and maintain a "revenue share" program with distributors, which we are currently formulating and which we intend to take into account the local factors and sales dynamics of each individual market.
In addition to utilizing local and regional distributor networks, we intend to use international trade shows and industry conferences to gain market exposure and brand recognition, such as Apimundia. We plan to work with leading entomologists and apiarists to enhance our marketing efforts.  As sales volume increases, we plan to open additional regional offices and to continue to manage sales activities in each of our defined geographical regions and to provide marketing support to local and regional distributors in each area.


With respect to the Argentine bee healthcare market, as noted above, we believe that there are at least 20 different products registered and approved by national regulatory authorities in Argentina that claim to treat one of the several reported causes of CCD.  Approximately half of the products are antibiotics and the other half are remedies against Varroa Acariasis, a condition caused by the varroa mite, a parasite that affects the bee population in many countries.  We believe that none of the products currently available in Argentina utilize our unique and proprietary chemical compounds, which contain antimicrobial agents and compounds to fight the invertebrate iridescent virus, and its interaction with the Nosema fungus, components to contrast the side effects of neonicotinoids used in pesticides.   In addition, we believe that the current accepted practice advocated by associations of entomologists and apiarists and cooperatives of beekeepers is to avoid the use of antibiotics in treating bees and CCD-related problems.  Our proprietary chemical compound does not contain antibiotics and also yields a high concentration of isoleucine, an amino acid commonly used by Argentine beekeepers to nourish their bees colonies.
In addition, we do not believe that the Argentina beekeeping market currently has a fully automated chemical compound distribution system like the BeesFree Dispenser, which will allow us to compete in the Argentine bee healthcare industry with respect to our chemical compound as well as our delivery system.
We believe that we also possess strategic advantages over potential competitors (e.g. Laboratorios Lavet, El Gigante, Roteh, Bayer Argentina) with respect to the value that we will deliver to customers.   Based upon our analysis of the Argentine market performed in October, we have determined that the prices of competitor products, which are generally limited to treating one CCD-related cause and therefore are not as comprehensive as our proprietary chemical compound, range from $45 to $70 per liter.  Although we believe that we will be able to price our product as the lowest in the market, at $40 per liter, and still maintain competitive gross profit margins.  Based upon our calculations, on a per month basis, the average end-user cost of our chemical compound that treats the comprehensive causes of CCD will be approximately $2 to $3 per colony per month, excluding the cost of the BeesFree Dispenser, as compared to $3 to $ 4.50 per colony per month, that only treats one cause of CCD, based upon polling of beekeepers at Apimondia, the world's largest conference and fair on the beekeeping industry, held in Buenos Aires in September 2011.
United States
As noted above, we believe that there is only one other company in the U.S., Beeologics, LLC, that is specifically focused on the bee healthcare industry.  Beeologics, LLC has recently been acquired by Monsanto Company, a global provider of agricultural products, which may provide Beeologics, LLC with significantly greater resources and opportunities than we possess at this time.
We believe Beeologics, LLC is currently focusing on the treatment of the Israeli Acute Paralysis Virus, which is just one of the generally accepted causes of the CCD syndrome.  Beeologics, LLC's products, to our knowledge, are not intended to treat other known causes of CCD, such as bacterial infections, fungi infections, damage caused by overuse of new generations of pesticides and the low immune defense system response level of bees.  However, our proprietary chemical compound and patent-pending product is designed to provide a complete bee healthcare remedy against what we believe to be the major causes of the CCD syndrome, including the invertebrate iridescent virus and its interaction with the Nosema fungus and neonicotinoids, which are used in pesticides.  In addition to Beeologics, LLC, there are several other manufacturers of vertical products that market specific CCD-related problems, such as anti-Varroa strips.
In addition, we believe that Beeologic, LLC's approach to the development of its bee healthcare products differs significantly from the design of our product.  Beeologics, LLC's product employs genetically modified RNAi, which is intended to introduce in the affected bee population a genetic resistance to the Israeli Acute Paralysis Virus.  We believe that the design of our proprietary chemical compound has certain advantages over Beeologic, LLC's products.  As noted above, our product is intended to treat the major causes of the CCD syndrome and, therefore, it contains antimicrobial agents and compounds to fight the invertebrate iridescent virus and its interaction with the Nosema fungus, components to contrast the side effects of neonicotinoids, which are used in pesticides and other nutrients and antioxidants.  In contrast, Beeologic, LLC's product is genetically designed to treat only the Israeli Acute Paralysis Virus.  In addition, because Beeologic, LLC's products are based upon genetically-engineered DNA and RNA, it may face a significantly more complex regulatory approval process in the U.S. than products that do not employ such technologies.  We believe that Beeologics, LLC will need to seek regulatory approval from the U.S. Food and Drug Administration, the Environmental Protection Agency and the IR4 agency, which could result in lengthy research, development, testing, manufacturing and regulatory processes.  Furthermore, products that are intended to genetically engineer DNA and RNA, such as the product developed by Beeologics, LLC, may be opposed by those groups with strong feelings against genetic modification.  We believe that our proprietary chemical compound, which consists of chemicals that have already been approved by the U.S. Food and Drug Administration in other products made by other manufacturers, may be subject to less regulatory scrutiny when we attempt to enter the U.S. market.  In addition, we believe that our proprietary chemical compound may serve as an alternative to those beekeepers who oppose the genetic modification of their bee population.  To our knowledge, Beeologics, LLC has begun the regulatory approval process for its first product and has been conducting field trials in Florida, Pennsylvania and Israel and a large scale clinical trial in the United States, but has not begun marketing this product.

We believe that there is no product currently available for sale that is similar to our proprietary BeesFree Dispenser.  Other bee healthcare products currently available are dispensed in various ways, depending upon the problem they claim to treat. For instance, for treatment against the varroa mite, there is a product consisting of strips of the active ingredient that are hung inside beehives.  Products consisting of antibiotics and nutrients are generally dispensed in liquid or granular form by receptacles located inside beehives.
In addition to the product developed by Beeologics, LLC, there are several chemical products already available that are intended to nourish bees with nutrients and antimicrobial substances.  We believe that our proprietary chemical compound is the only mixture being marketed for the bee population that combines antimicrobial agents and compounds to fight the invertebrate iridescent virus and its interaction with the Nosema fungus with other components that contrast the side effects of neonicotinoids and other nutrients and antioxidants.
We believe that our existing advantages will allow us to maintain a competitive edge over potential competitors for a sufficient period of time to provide us with the opportunity to establish a presence in key markets, and to generate revenues that will be reinvested in the research and development of new products and technologies.  We intend to spend at least 10% of our gross margin on an annual basis on research and development, primarily to cover the costs of recruiting and retaining talented and skilled technical personnel and ensure that we are at the forefront of bee healthcare technology.
However, there are also numerous competitive disadvantages that we face with respect to both our products and the bee healthcare industry as a whole.  As a development stage company, we lack the significant resources of larger companies, or of smaller competitors, such as Beeologics, LLC, that are subsidiaries of larger companies.  Without these significant resources, we may not be able to focus on research and development, marketing and sales of our products to the same degree as companies with more substantial resources.  Furthermore, we believe that our international sales strategy is the most effective method of marketing and selling our product for a company of our size.  However, we may face significant challenges in managing different sales teams that are located on different continents.  Additionally, larger companies with more established distribution channels in the bee healthcare industry may be able to more effectively market products that could hinder the acceptance of our proprietary chemical compound.  Also, we cannot be certain that other companies have not developed similar technologies as those found in our products.  In the event that our products are substantially similar to other products being marketed to the international beekeeping industry, we may not be able to achieve the market share or growth that we predict that we will achieve.




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#486   Here we go! AJ_33 02/10/21 12:30:58 PM
#485   Looks like there’s some activity here. RM may AJ_33 09/16/20 01:18:30 PM
#484   BEES volume coming back looking good HallaDurg 09/02/20 11:47:03 AM
#483   Something is brewing... AJ_33 09/02/20 11:22:42 AM
#482   I caught it to late as well. Wish Meangene818 12/04/19 07:50:39 PM
#481   Wow big dump to .0065. Missed those shares. HallaDurg 12/04/19 02:25:08 PM
#480   Dead? Penny2Dime 09/22/19 02:43:17 PM
#479   Close, .09 777 06/15/19 01:43:07 PM
#478   We should easily break .10 today next stop Daytrader2013 06/14/19 08:49:01 AM
#477   Literally none of this matters. ALL Custodianships 777 06/13/19 07:13:20 PM
#476   Omg give me a break. They haven’t 777 06/13/19 07:11:56 PM
#475   A lot of these RM plays don't necessarily HallaDurg 06/13/19 03:10:28 PM
#474   Is that where all the bid support is 777 06/13/19 01:54:13 PM
#473   Loll batyrider 06/13/19 01:46:45 PM
#472   Something come out here? jonnyvs 06/13/19 12:47:46 PM
#471   Based on the DD it's a pretty good Big Brother 06/13/19 12:40:54 PM
#470   Huge bid nice attorney letter should be out anyday Daytrader2013 06/13/19 10:20:31 AM
#469   Attorney letter will be out soon Daytrader2013 06/12/19 09:40:19 AM
#468   This is pretty huge, low float RM this Daytrader2013 06/08/19 08:50:35 PM
#467   I've done a little bit of research into Big Brother 06/08/19 12:32:18 PM
#466   agree peterus 06/01/19 07:21:39 AM
#465   I believe the selling is from people who HallaDurg 06/01/19 01:31:53 AM
#464   I will get a starter position soon. I Seventh_Level 05/31/19 07:48:10 PM
#463   They are manipulating the bid. They keep tapping HallaDurg 05/30/19 01:44:04 PM
#462   on little volume15k - 35k every day going peterus 05/30/19 01:11:01 PM
#461   Absolutely. Having world Financial holding group being a Daytrader2013 05/28/19 09:08:24 AM
#460   I believe we will set new highs above HallaDurg 05/27/19 11:37:10 PM
#459   What is your predictions? msjcecil3 05/27/19 09:33:00 PM
#458   BEES bought by World Financial Holding Group last Daytrader2013 05/27/19 05:56:13 PM
#457   When will that happen? msjcecil3 05/23/19 11:24:31 PM
#456   Bought some today. Merger news will send this Guelo 05/23/19 10:45:08 AM
#455   Loading up these levels!!! Merger hasn’t even been Jcazz 05/23/19 05:32:01 AM
#454   bought some today sooner or later this will peterus 05/22/19 10:54:10 PM
#453   MM's have anyone's detailed information, never let you Penny2Dime 05/22/19 09:31:06 PM
#452   True. Have dumped the other pos and bought LETSWIN2020 05/22/19 05:13:12 PM
#451   i like could peterus 05/22/19 03:30:11 PM
#441   No,no,no. Closes under a dime. Won’t hold up Oger 05/22/19 10:09:50 AM
#440   5k sold under .10. Look at the bids stacking OmegaMoney29 05/22/19 10:04:21 AM
#439   You sold 200 shares to gap it down Daytrader2013 05/22/19 10:01:45 AM
#438   What did I tell you kids? Under a Oger 05/22/19 10:00:13 AM
#437   Here we go OmegaMoney29 05/22/19 09:54:36 AM
#436   Lol too funny Daytrader2013 05/22/19 09:53:32 AM
#435   Dip and rip. 200 shares dumped at 8 OmegaMoney29 05/22/19 09:40:02 AM
#434   Good luck OmegaMoney29 05/22/19 09:27:34 AM
#432   No bashing. It’s going under a dime today. Oger 05/22/19 09:08:12 AM
#429   There was no hidden bids at 14. dinogreeves 05/21/19 08:44:22 PM
#427   Well below .10 by tomorrow Oger 05/21/19 06:58:26 PM
#426   There was hiding bid at 0.14 !! Penny2Dime 05/21/19 06:19:33 PM
#425   Look how well it held above .10 Daytrader2013 05/21/19 05:15:36 PM
#424   ALOT more coming$$$$ Daytrader2013 05/21/19 05:04:45 PM
Consent Preferences